MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-17-2026
West Pharmaceutical Services Gross Profit 2011-2026 | WST
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit West Pharmaceutical Services
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.1 B | 998 M | 1.13 B | 1.14 B | 1.18 B | 768 M | 606 M | 545 M | 513 M | 501 M | 456 M | 448 M | 435 M | 388 M | 339 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.18 B | 339 M | 703 M |
Quarterly Gross Profit West Pharmaceutical Services
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 294 M | 274 M | 232 M | - | 265 M | 230 M | 230 M | - | 288 M | 291 M | 271 M | - | 268 M | 322 M | 285 M | - | 288 M | 315 M | 272 M | 211 M | 195 M | 195 M | 167 M | 153 M | 148 M | 158 M | 147 M | - | 136 M | 142 M | 134 M | - | 125 M | 125 M | 134 M | - | 121 M | 133 M | 123 M | - | 108 M | 118 M | 110 M | - | 110 M | 122 M | 106 M | - | 106 M | 111 M | 112 M | - | 90.4 M | 98.7 M | 101 M | - | 81.4 M | 84.6 M | 88 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 322 M | 81.4 M | 175 M |
Gross Profit of other stocks in the Medical instruments industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
62.4 K | - | - | $ 810 M |  USA |
 |
Becton, Dickinson and Company
BDX
|
8.29 B | $ 154.51 | -1.17 % | $ 44.4 B | USA |
 |
Luminex Corporation
LMNX
|
248 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
479 K | - | -9.52 % | $ 20.6 M | USA |
 |
Repligen Corporation
RGEN
|
151 M | $ 117.78 | -0.46 % | $ 6.56 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
86.5 M | - | - | $ 955 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
6.84 M | $ 9.4 | -11.74 % | $ 22.8 M | USA |
 |
Cantel Medical Corp.
CMD
|
436 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
1.68 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
1.48 B | - | -0.05 % | $ 10.3 B | USA |
 |
Haemonetics Corporation
HAE
|
749 M | $ 56.83 | 1.05 % | $ 2.86 B | USA |
 |
ICU Medical
ICUI
|
822 M | $ 123.31 | -1.53 % | $ 3.04 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
1.38 B | - | -0.02 % | $ 16.3 B | USA |
 |
Intuitive Surgical
ISRG
|
6.64 B | $ 452.07 | -2.67 % | $ 161 B | USA |
 |
Harvard Bioscience
HBIO
|
49.9 M | $ 5.2 | 2.16 % | $ 231 M | USA |
 |
Isoray
ISR
|
817 K | - | 0.03 % | $ 108 M | USA |
 |
AngioDynamics
ANGO
|
158 M | $ 10.31 | -13.65 % | $ 421 M | USA |
 |
Repro Med Systems
KRMD
|
25.6 M | $ 4.32 | 1.17 % | $ 200 M | USA |
 |
AtriCure
ATRC
|
401 M | $ 29.07 | 2.68 % | $ 1.39 B | USA |
 |
InfuSystem Holdings
INFU
|
62.6 M | $ 9.29 | -0.11 % | $ 192 M | USA |
 |
Masimo Corporation
MASI
|
1 B | $ 178.59 | 0.33 % | $ 9.52 B | USA |
 |
iRhythm Technologies
IRTC
|
527 M | $ 116.8 | -1.2 % | $ 3.74 B | USA |
 |
Merit Medical Systems
MMSI
|
738 M | $ 67.7 | -0.78 % | $ 4 B | USA |
 |
BioLife Solutions
BLFS
|
18.6 M | $ 19.51 | 1.14 % | $ 899 M | USA |
 |
electroCore
ECOR
|
27.8 M | $ 6.8 | 3.03 % | $ 57.7 K | USA |
 |
STERIS plc
STE
|
2.4 B | $ 218.71 | -0.56 % | $ 21.6 B | USA |
 |
Teleflex Incorporated
TFX
|
307 M | $ 117.81 | -0.52 % | $ 5.26 B | USA |
 |
Utah Medical Products
UTMD
|
5.26 M | $ 63.12 | 0.4 % | $ 205 M | USA |
 |
OraSure Technologies
OSUR
|
48.2 M | $ 3.08 | 0.98 % | $ 226 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
1.84 B | $ 11.63 | -0.26 % | $ 2.32 B | USA |
 |
Glaukos Corporation
GKOS
|
239 M | $ 112.77 | 0.12 % | $ 5.46 B | USA |
 |
ResMed
RMD
|
2.02 B | $ 224.09 | 0.56 % | $ 32.7 B | USA |
 |
Predictive Oncology
POAI
|
1.02 M | - | - | $ 31.1 M | USA |
 |
Baxter International
BAX
|
3.38 B | $ 16.68 | -0.6 % | $ 8.56 B | USA |
 |
NeuroMetrix
NURO
|
1.68 M | - | 5.05 % | $ 9.02 M | USA |
 |
STAAR Surgical Company
STAA
|
182 M | $ 20.21 | 4.55 % | $ 1 B | USA |
 |
Stereotaxis
STXS
|
17.1 M | $ 1.87 | 1.08 % | $ 170 M | USA |
 |
The Cooper Companies
COO
|
2.68 B | $ 70.17 | -1.76 % | $ 14 B | USA |
 |
LeMaitre Vascular
LMAT
|
179 M | $ 108.49 | -0.24 % | $ 2.46 B | USA |
 |
Microbot Medical
MBOT
|
117 K | $ 2.4 | 1.27 % | $ 110 M |  Israel |
 |
Nephros
NEPH
|
8.4 M | $ 2.87 | -2.21 % | $ 29.8 M | USA |
 |
Envista Holdings Corporation
NVST
|
1.49 B | $ 25.81 | -0.35 % | $ 4.34 B | USA |
 |
Milestone Scientific
MLSS
|
6.41 M | $ 0.28 | -4.86 % | $ 23 M | USA |
 |
Alcon
ALC
|
5.74 B | $ 74.56 | -1.26 % | $ 40.4 B |  Schweiz |
 |
Pro-Dex
PDEX
|
19.5 M | $ 51.67 | 1.33 % | $ 170 M | USA |
 |
Retractable Technologies
RVP
|
47 K | $ 0.69 | 2.99 % | $ 20.7 M | USA |